What changed in this filing

/stocks — the workspaceLOADING

Item 1. Financial Statements

2013-08-02 compared with 2013-05-06 · 137 added, 89 removed, 338 unchanged (40% of the section changed)

4 unchanged sentences

In the opinion of management, the consolidated financial statements contain all material adjustments, consisting only of normal recurring adjustments necessary to present fairly the financial condition, results of operations, and cash flows of the Company for the interim periods presented.

The results for the three months ended March 31, 2013 are not necessarily indicative of the results of operations for the full year.

The results for the three and six months ended June 30, 2013 are not necessarily indicative of the results of operations for the full year.

These financial statements and related footnotes should be read in conjunction with the consolidated financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 filed with the Securities and Exchange Commission on March 22, 2013.

2 unchanged sentences

CONDENSED BALANCE SHEETS

MARCH 31, 2013 (UNAUDITED) AND DECEMBER 31, 2012

JUNE 30, 2013 (UNAUDITED) AND DECEMBER 31, 2012

CURRENT ASSETS

Prepaid expenses

Total current assets

Intellectual Property

LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)

LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES

Accounts payable and accrued expenses

Liability for stock to be issued

Short - term loans

3 unchanged sentences

TOTAL LIABILITIES

STOCKHOLDERS' EQUITY (DEFICIENCY)

Common stock, $0.001 par value, 200,000,000 shares authorized, 116,578,612 and 101,085,862 shares issued and outstanding as of March 31, 2013 and December 31, 2012, respectively

STOCKHOLDERS' EQUITY

Common stock, $0.001 par value, 200,000,000 shares authorized,

156,943,593 and 101,085,862 shares issued and outstanding as of

June 30, 2013 and December 31, 2012, respectively

Additional paid in capital

3 unchanged sentences

Accumulated other comprehensive loss

Total stockholders' equity (deficiency)

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)

Total stockholders' equity

TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY

The accompanying notes are an integral part of these financial statements.

2 unchanged sentences

CONDENSED STATEMENTS OF OPERATIONS AND ACCUMULATED OTHER COMPREHENSIVE LOSS (UNAUDITED)

FOR THE THREE MONTHS ENDED MARCH 31, 2013 AND 2012 AND DEVELOPMENT STAGE OCTOBER 1, 2011 THROUGH MARCH 31, 2013

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2013 AND 2012 AND DEVELOPMENT STAGE OCTOBER 1, 2011 THROUGH JUNE 30, 2013

DEVELOPMENT STAGE

OCTOBER 1, 2011 to

JUNE 30, 2013

JUNE 30, 2012

JUNE 30, 2013

JUNE 30, 2012

JUNE 30, 2013

COST OF REVENUES

5 unchanged sentences

OPERATING EXPENSES

Professional fees

Professional fees/stock based compensation

Amortization expense and impairment

14 unchanged sentences

CONDENSED STATEMENTS OF CASH FLOW (UNAUDITED)

FOR THE THREE MONTHS ENDED MARCH 31, 2013 AND 2012 AND DEVELOPMENT STAGE OCTOBER 1, 2011 THROUGH MARCH 31, 2013

FOR THE THREE MONTHS ENDED JUNE 30, 2013 AND 2012 AND DEVELOPMENT STAGE OCTOBER 1, 2011 THROUGH JUNE 30, 2013

DEVELOPMENT STAGE

OCTOBER 1, 2011 THROUGH

JUNE 30, 2013

JUNE 30, 2012

JUNE 30, 2013

CASH FLOWS FROM OPERATING ACTIVITIES:

Adjustments to reconcile net loss

to net cash used in operating activities:

Adjustments to reconcile net loss to net cash used in operating activities:

Impairment expense

2 unchanged sentences

Change in assets and liabilities

(Increase) decrease in prepaids

(Increase) decrease in inventory

Increase (decrease) in accounts payable and accrued expenses

7 unchanged sentences

Effect of foreign currency

NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS

NET INCREASE IN CASH AND CASH EQUIVALENTS

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD

8 unchanged sentences

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION

17 unchanged sentences

All inventories from the former products were written off as of October 1, 2011.

The Type 2 Defense product is currently under development with the initial shipment expected at the end of June 2013.

The Company has elected to enter the development stage on October 1, 2011 and expects to emerge from the development stage at the end of June 2013.

The Company elected to enter the development stage on October 1, 2011 and will emerge from the development stage during July 2013.

During October 2012, the board of directors increased the number of common shares authorized from 90,000,000 to 200,000,000 shares.

During February 2013, the Company began the first production run of the Type 2 Defense product.

The Company expects the product will be completed in May 2013 with sales in June 2013.

The first production run of the Type 2 Defense product was completed during June 2013 and the initial shipment occurred in early July 2013.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 1 - ORGANIZATION AND BASIS OF PRESENTATION (CONTINUED)

17 unchanged sentences

The Company’s primary activities since October 1, 2011 have been performing business, strategic and financial planning, enhancing the Type2 Defense formula and securing capital for ongoing operations.

The Company began shipping product to customers in early July 2013 and will emerge from the development stage during the third quarter of 2013.

Use of Estimates

3 unchanged sentences

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

4 unchanged sentences

Gains and losses from foreign currency transactions are included in other income (expense) in the results of operations.

For the three months ended March 31, 2012, the Company recorded $6,514 in translation losses.

For the three and six months ended June 30, 2012, the Company recorded $6,575 and $61 in translation gains, respectively.

Comprehensive Income (Loss)

18 unchanged sentences

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

11 unchanged sentences

The Company has not issued any options or warrants to date.

At March 31, 2013, the total shares issuable upon conversion of convertible notes payable would be 7,967,325 shares of the Company’s common stock.

At June 30, 2013, the total shares issuable upon conversion of convertible notes payable would be 17,019,281 shares of the Company’s common stock.

Inventory is stated at the lower of cost (FIFO:

1 unchanged sentence

The cost of finished goods includes the cost of packaging supplies, direct and indirect labor and other indirect manufacturing costs.

As of March 31, 2013, the Company had no inventory.

As of June 30, 2013, the Company had inventory of $43,903.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

Recent Issued Accounting Standards

In May 2011, FASB issued Accounting Standards Update (ASU) No.

2011-04, Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S.

GAAP and IFRSs .

FASB ASU 2011-04 amends and clarifies the measurement and disclosure requirements of FASB ASC 820 resulting in common requirements for measuring fair value and for disclosing information about fair value measurements, clarification of how to apply existing fair value measurement and disclosure requirements, and changes to certain principles and requirements for measuring fair value and disclosing information about fair value measurements.

The new requirements are effective for fiscal years beginning after December 15, 2011.

The Company plans to adopt this amended guidance on October 1, 2012 and at this time does not anticipate that it will have a material impact on the Company’s results of operations, cash flows or financial position.

In September 2011, FASB issued ASU No.

2011-05, Presentation of Comprehensive Income , which amends the disclosure and presentation requirements of Comprehensive Income.

Specifically, FASB ASU No.

2011-05 requires that all non-owner changes in stockholders’ equity be presented either in 1) a single continuous statement of comprehensive income or 2) two separate but consecutive statements, in which the first statement presents total net income and its components, and the second statement presents total other comprehensive income and its components.

These new presentation requirements, as currently set forth, are effective for the Company beginning October 1, 2012, with early adoption permitted.

In September 2011, FASB issued ASU 2011-08, Testing Goodwill for Impairment , which amended goodwill impairment guidance to provide an option for entities to first assess qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

After assessing the totality of events and circumstances, if an entity determines that it is not more likely than not that the fair value of a reporting unit is less than its carrying amount;

performance of the two-step impairment test is no longer required.

This guidance is effective for annual and interim goodwill impairment tests performed for fiscal years beginning after December 15, 2011, with early adoption permitted.

Adoption of this guidance is not expected to have any impact on the Company’s results of operations, cash flows or financial position.

In July 2012, the FASB issued ASU 2012-02, Intangibles – Goodwill and Other (Topic 350):

6 unchanged sentences

The Company’s adoption of this accounting guidance does not have a material impact on the consolidated financial statements and related disclosures.

In February 2013, the FASB issued ASU 2013-05, Foreign Currency Matters (Topic 830):

Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity, The standard requires that companies present either in a single note or parenthetically on the face of the financial statements, the effect of significant amounts reclassified from each component of accumulated other comprehensive income based on its source (e.g., the release due to cash flow hedges from interest rate contracts) and the income statement line items affected by the reclassification (e.g., interest income or interest expense).

If a component is not required to be reclassified to net income in its entirety (e.g., the net periodic pension cost), companies would instead cross reference to the related footnote for additional information (e.g., the pension footnote).

The amendments to U.S.

GAAP will be effective for fiscal years starting after December 15, 2012.

The Company is currently assessing the impact of this accounting guidance on the consolidated financial statements and related disclosures.

There were other updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to have a material impact on the Company’s financial position, results of operations or cash flows.

1 unchanged sentence

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 3 - STOCKHOLDERS’ EQUITY

3 unchanged sentences

On March 27, 2011, the Company filed Form S-8 for the 2011 Stock Incentive and Equity Compensation Plan for 20,000,000 registered shares of the Company’s common stock.

The Company issued 4,070,000 and 15,641,000 shares under this plan during the year ended December 31, 2012 and 2011, respectively.

The Company issued 19,711,000 shares under this plan.

During April 2012, the Company issued 100,000 unregistered shares of the Company’s common stock to settle a notes payable and related accrued interest.

29 unchanged sentences

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 3 - STOCKHOLDERS’ EQUITY (CONTINUED)

7 unchanged sentences

The shares were issued on April 23, 2013.

These shares are reflected in the liability for common stock to be issued at March 31, 2013.

During January 2013, a consultant was granted 625,000 registered shares of the Company’s common stock in their S-8 registration filed March 2013 for marketing services to the Company.

6 unchanged sentences

During February 2013, a consultant was granted 4,500,000 registered shares of the Company’s common stock in their S-8 registration filed March 2013 for marketing services to the Company.

The Company issued 3,000,000 shares on April 23, 2013 and withheld the remaining 1,500,000 shares pending the consultant fulfilling certain performance obligations under the agreement.

The 3,000,000 shares were valued at $56,700 or $0.0189 per share.

These shares are reflected in the liability for common stock to be issued at March 31, 2013.

The Company issued 3,000,000 shares on April 23, 2013 and issued the remaining 1,500,000 shares on June 10, 2013 upon fulfilling certain performance obligations under the agreement.

The 3,000,000 shares were valued at $56,700 or $0.0189 per share and the 1,500,000 shares were valued at $19,500 or $.013 per share for an aggregate of $76,200.

During March 2013, a consultant was granted 4,500,000 registered shares of the Company’s common stock in their S-8 registration filed March 2013 for marketing services to the Company.

The Company issued 3,000,000 shares on April 22, 2013 and withheld the remaining 1,500,000 shares pending the consultant fulfilling certain performance obligations under the agreement.

The 3,000,000 shares were valued at $69,000 or $0.023 per share.

These shares are reflected in the liability for common stock to be issued at March 31, 2013.

The Company issued 3,000,000 shares on April 22, 2013 and issued the remaining 1,500,000 shares on June 10, 2013 upon fulfilling certain performance obligations under the agreement.

The 3,000,000 shares were valued at $69,000 or $0.023 per share and the 1,500,000 shares were valued at $19,500 or $.013 per share for an aggregate of $88,500.

On March 4, 2013, the Company filed a Form S-8 with the Security and Exchange Commission.

The 2013 Stock Incentive Plan may issue up to 30,000,000 registered shares of the Company’s common stock for services to the Company.

The Company granted 14,625,000 shares under this plan during the three months ended March 31, 2013 and an additional 500,000 shares in April 2013.

The Company granted 9,500,000 and 18,125,000 shares under this plan during the three and six months ended June 30, 2013, respectively.

During March 2013, a convertible promissory note was partially converted into unregistered shares of the Company’s common stock.

2 unchanged sentences

The shares were issued on April 3, 2013.

These shares are reflected in the liability for common stock to be issued at March 31, 2013.

As of March 31, 2013, the Company has 116,578,612 shares of common stock issued and outstanding.

During April 2013, the Company issued 500,000 registered shares of the Company’s common stock in their S-8 registration filed March 2013 to settle an accounts payable.

These shares were valued at $0.0128 per share or $6,375.

During April 2013, a convertible promissory note was converted into unregistered shares of the Company’s common stock.

The amount totaled $10,266 including interest was converted into 1,466,537 unregistered shares of the Company’s common stock at $0.007 per share.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 3 - STOCKHOLDERS’ EQUITY (CONTINUED)

During May 2013 a consultant was granted 100,000 unregistered shares of the Company’s common stock for investor relation services to the Company.

These shares were valued at $1,410 or $0.0141 per share.

During May 2013, a convertible promissory note was converted into unregistered shares of the Company’s common stock.

The amount totaled $7,175 including interest was converted into 1,025,000 unregistered shares of the Company’s common stock at $0.007 per share.

During June 2013, a director was issued 2,500,000 unregistered shares of the Company’s common stock for marketing services compensation.

These shares were valued at $0.015 per share or $37,500.

During June 2013, an employee was issued 3,500,000 unregistered shares of the Company’s common stock for website services and salary compensation.

These shares were valued at $0.015 per share or $52,500.

During June 2013, a consultant was issued 2,500,000 unregistered shares of the Company’s common stock for warehousing and fulfillment services compensation.

These shares were valued at $0.015 per share or $37,500.

During June 2013, our chief executive officer was issued 15,000,000 unregistered shares of the Company’s common stock for fulfilling provisions in the Type2 acquisition agreement dated September 26, 2011.

These shares were valued at $0.015 per share or $225,000.

During June 2013, a consultant was issued 2,500,000 unregistered shares of the Company’s common stock for investor relations compensation.

These shares were valued at $0.015 per share or $37,500.

As of June 30, 2013, the Company has 156,943,593 shares of common stock issued and outstanding.

The Company has not issued any options or warrants to date.

1 unchanged sentence

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 4 - RELATED PARTY TRANSACTIONS

2 unchanged sentences

This arrangement terminated on April 1, 2012.

Rent expense was $599 for the three months ended March 31, 2012.

Rent expense was $599 for the six months ended June 30, 2012.

NOTE 5 - SHORT-TERM LOANS

1 unchanged sentence

The loan bears interest at 5% and is payable on demand.

The unpaid balance including accrued interest was $12,100 at March 31, 2013.

This noted is included as short-term loans on the condensed balance sheet.

The unpaid balance including accrued interest was $12,250 at June 30, 2013.

This note is included as short-term loans on the condensed balance sheet.

NOTE 6 - SHORT-TERM LOANS - RELATED PARTY

1 unchanged sentence

The advance is evidenced by a demand promissory note bearing interest at 5% per annum.

The unpaid balance including accrued interest was $1,616 and $1,597 at March 31, 2013 and December 31, 2012, respectively.

This noted is included as short-term loans – related party on the condensed balance sheet.

The unpaid balance including accrued interest was $1,635 and $1,597 at June 30, 2013 and December 31, 2012, respectively.

This note is included as short-term loans – related party on the condensed balance sheet.

NOTE 7 - CONVERTIBLE NOTES PAYABLE

9 unchanged sentences

After the due date, the interest rate on the convertible note increased to 15%.

The unpaid balance including accrued interest was $2,735 and $2,641 at March 31, 2013 and December 31, 2012, respectively.

The unpaid balance including accrued interest was $2,829 and $2,641 at June 30, 2013 and December 31, 2012, respectively.

The Company is not compliant with the repayment terms of the note.

1 unchanged sentence

The loan bears interest at 5% and has a maturity date of November 10, 2012.

In addition, at any time, the Company’s CFO may convert the note into shares of the Company’s common stock at an exercise price of $.009 per share.

In addition, at any time, the Company’s CEO may convert the note into shares of the Company’s common stock at an exercise price of $.009 per share.

After the due date, the interest rate on the convertible note increases to 15%.

The unpaid balance including accrued interest was $2,812 and $2,714 at March 31, 2013 and December 31, 2012, respectively.

During June 2013, the Company paid the principle balance of $2,600 to the Company’s CEO.

The unpaid balance including accrued interest was $309 and $2,714 at June 30, 2013 and December 31, 2012, respectively.

The Company is not compliant with the repayment terms of the note.

11 unchanged sentences

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 7 - CONVERTIBLE NOTES PAYABLE (CONTINUED)

3 unchanged sentences

During April 2013, $10,266 including accrued interest was converted into 1,466,537 unregistered shares of the Company’s common stock at $0.007 per share to fully satisfy the promissory note.

The unpaid balance including accrued interest was $10,230 and $10,105 at March 31, 2013 and December 31, 2012, respectively.

The unpaid balance including accrued interest was $10,105 at December 31, 2012.

On November 23, 2012, the Company issued a $7,000 convertible note to an individual.

1 unchanged sentence

In addition, at any time, the individual may convert the note into shares of the Company’s common stock at an exercise price of $.007 per share.

The unpaid balance including accrued interest was $7,125 and $7,037 at March 31, 2013 and December 31, 2012, respectively.

During May 2013, $7,175 including accrued interest was converted into 1,025,000 unregistered shares of the Company’s common stock at $0.007 per share to fully satisfy the promissory note.

The unpaid balance including accrued interest was $7,037 December 31, 2012.

On January 28, 2013, the Company issued a $12,500 convertible note to an individual.

2 unchanged sentences

The conversion price shall not be lower than $0.01 per share.

The unpaid balance including accrued interest was $12,604 at March 31, 2013.

The unpaid balance including accrued interest was $12,760 at June 30, 2013.

On January 30, 2013, the Company issued a $7,500 convertible note to an individual.

1 unchanged sentence

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.005 per share.

The unpaid balance including accrued interest was $7,563 at March 31, 2013.

The unpaid balance including accrued interest was $7,656 at June 30, 2013.

On February 20, 2013, the Company issued a $7,500 convertible note to an individual.

1 unchanged sentence

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.005 per share.

The unpaid balance including accrued interest was $7,547 at March 31, 2013.

The unpaid balance including accrued interest was $7,641 at June 30, 2013.

On February 26, 2013, the Company issued a $12,500 convertible note to an individual.

2 unchanged sentences

The conversion price shall not be lower than $0.01 per share.

The unpaid balance including accrued interest was $12,552 at March 31, 2013.

As of March 31, 2013, the total short-term loans - convertible amounted to $63,168 including $1,068 of accrued interest.

The unpaid balance including accrued interest was $12,708 at June 30, 2013.

On April 30, 2013, the Company issued a $10,000 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of October 30, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.005 per share.

The unpaid balance including accrued interest was $10,083 at June 30, 2013.

On April 30, 2013, the Company issued a $10,000 convertible note to an individual.

The loan bears interest at 10% and has a maturity date of October 30, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.01 per share.

The unpaid balance including accrued interest was $10,167 at June 30, 2013.

On May 27, 2013, the Company issued a $12,500 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of November 27, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.005 per share.

The unpaid balance including accrued interest was $12,552 at June 30, 2013.

On June 10, 2013, the Company issued a $6,500 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of August 11, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.0065 per share.

The unpaid balance including accrued interest was $6,514 at June 30, 2013.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 7 - CONVERTIBLE NOTES PAYABLE (CONTINUED)

On June 10, 2013, the Company issued a $6,222 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of August 11, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.0065 per share.

The unpaid balance including accrued interest was $6,235 at June 30, 2013.

On June 10, 2013, the Company issued a $6,500 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of August 11, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.0065 per share.

The unpaid balance including accrued interest was $6,514 at June 30, 2013.

On June 18, 2013, the Company issued a $12,500 convertible note to an individual.

The loan bears interest at 5% and has a maturity date of December 18, 2013.

In addition, at any time, the holder may convert the note into shares of the Company’s common stock at an exercise price of $.005 per share.

The unpaid balance including accrued interest was $12,526 at June 30, 2013.

As of June 30, 2013, the total short-term loans - convertible amounted to $122,379 including $2,157 of accrued interest.

The conversion price of the notes were fixed and determinable on the date of issuance and as such in accordance with ASC Topic 815 “ Derivatives and Hedging ” (“ASC 815”), the embedded conversion options of the note were not considered derivative liabilities.

The beneficial conversion features of the convertible notes are at a price below fair market value.

The Company recorded interest expense of $42,074 during the three months ended March 31, 2013, in the accompanying condensed statement of operations for the beneficial conversion feature based on the fair market value of $0.0159 per share of the Company’s common stock at March 31, 2013.

The Company recorded interest expense of $57,754 and $162.356 during the three months ended June 30, 2013 and 2012 respectively, and $121,266 and $162,356 during the six months ended June 30, 2013 and 2012 respectively, in the accompanying condensed statement of operations for the beneficial conversion feature based on the fair market value of $0.0135 and $.02 per share of the Company’s common stock at June 30, 2013 and 2012, respectively.

NOTE 8 - MAJOR CUSTOMERS

The Company generated no sales during the three months ended March 31, 2013, and 2012.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

The Company generated no sales during the three and six months ended June 30, 2013, and 2012.

NOTE 9 - CONVERSION OF ACCOUNTS PAYABLE AND NOTES PAYABLE TO EQUITY

2 unchanged sentences

Chaumillon agreed to settle his outstanding debt, interest and account payable balances of $227,811 for $10,000 payable in ten equal monthly installments of $1,000 beginning July 2012.

At June 30, 2012, the Company wrote-of the net amount of $217,811 as a conversion of accounts payable and notes payable to equity.

At March 31, 2013, Mr.

At June 30, 2012, the Company wrote-off the net amount of $217,811 as a conversion of accounts payable and notes payable to equity.

At June 30, 2013, Mr.

Chaumillon is owed $9,000.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

JUNE 30, 2013 AND 2012 (UNAUDITED)

NOTE 10 - INTELLECTUAL PROPERTY

6 unchanged sentences

The issuance of 10,000,000 shares of the Company’s common stock upon reaching 1,500 customers was reduced by the advance to 9,400,000 shares.

As of May 6, 2013, the agreement provisions for achieving operational milestones for 10,000,000 shares of the Company’s common stock and reaching 1,500 customers for 9,400,000 shares of the Company’s common stock have not been achieved.

During June 2013, the Company achieved the operational milestones as specified in the September 26, 2011 Type 2 Defense acquisition agreement.

On June 18, 2013, the Company issued 10,000,000 shares to the Company’s CEO for the Type2 Defense product meeting the operational milestones.

The shares were valued at $0.015 per share or $150,000 and included as intellectual property on the accompanying condensed balance sheet.

In addition, on June18, 2013, an advance of 5,000,000 shares of the Company’s common stock related to reaching of 1,500 customers’ milestone in the original agreement was approved by the board of directors and issued to the Company’s CEO.

The shares were valued at $0.015 per share or $75,000 and included as intellectual property on the accompanying condensed balance sheet.

As of August 02, 2013, the agreement provisions for reaching 1,500 customers for 4,400,000 shares of the Company’s common stock was achieved during early July and the remaining shares will be issued by September 30, 2013.

All assets other than the intellectual property had a fair value of $0, with the intellectual property being valued at $431,600.

14 unchanged sentences

Instruments with primarily unobservable value drivers.

BIO-SOLUTIONS CORP.

NOTES TO CONDENSED FINANCIAL STATEMENTS

MARCH 31, 2013 AND 2012 (UNAUDITED)

NOTE 12 - SUBSEQUENT EVENTS

During April 2013, a consultant was issued 500,000 registered shares of the Company’s common stock in their S-8 registration filed in March 2013 for accounting and finance services to the Company.

These shares were valued at $6,375 or $0.0128 per share.

During April 2013, a convertible promissory note totaling $10,265.76 including interest was fully converted into 1,466,537 unregistered shares of the Company’s common stock at $0.007 per share.

The Company evaluates events that have occurred after the balance sheet date but before the financial statements are issued.

1 unchanged sentence

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-Q

Item 1. Financial Statements